Recently, Prisys Biotechnologies Co., Ltd. (hereinafter referred to as "Prisys") has achieved Full Accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International), confirming its commitment to maintaining the highest standards in experimental animal quality, welfare, and biosafety on an international level.
AAALAC accreditation represents the pinnacle of standards in experimental animal quality, welfare, and biosafety. It serves as a crucial assurance of the quality of biomedical research globally, providing significant support for Prisys's engagement in international scientific collaboration and competition. Obtaining Full Accreditation from AAALAC signifies that Prisys's experimental facilities, encompassing both hardware and software, including animal welfare, environmental hygiene, supervision, and system development, meet the highest international standards for the management of laboratory animals and research activities.
Looking ahead, Prisys remains committed to strictly adhering to AAALAC requirements. We will further enhance the construction of non-clinical drug technology systems, continuously focus on animal welfare, adhere to internationally recognized standards for the use of laboratory animals, and rigorously control the quality of experimental animals. We are dedicated to providing standardized and efficient non-clinical evaluation research technology services for pharmaceutical companies and drug research institutions at home and abroad, aiming to become the most reliable partner for global pharmaceutical innovators.
About Prisys
Prisys Biotechnologies Co., Ltd. is a high-tech enterprise and a specialized small and medium-sized enterprise in Shanghai dedicated to preclinical and preclinical evaluation of new drugs and new drug technology development.
Prisys is committed to becoming a leader in large animal pharmacology and efficacy research, providing services such as disease models, pharmacological efficacy research, safety evaluation, biomarker research, and mechanism concept validation based on multiple experimental species including non-human primates (NHP) and laboratory dogs. Disease models cover multiple areas including the nervous system, cardiovascular system, metabolic system, and renal system.
In 2022, Prisys completed the construction of a pharmaceutical industry-standard translational medicine center, which will fully integrate NHP model development, clinical-level research activities, industrial-scale research capabilities, and high-standard animal welfare.
